Docs react: A rare FDA move shakes up the future of mRNA flu vaccines
Industry Buzz
I'm open to harsher scrutiny toward pharmaceuticals. They aren't anyone's friends. They absolutely will push questionable efficacy if it means more money. But the heads of the FDA right now are charlatans. They are not rejecti[ng] based on sound literature.
—Canadian GP @ldnk via Reddit
Didn't have being on the same side as Big Pharma on my bingo card but here I am.
—Emergency medicine physician @AllDayEmergency via Reddit
In a surprise regulatory move, the FDA has refused to consider Moderna’s application for a new mRNA-based influenza vaccine, citing flaws in the clinical study design, rather than product safety or efficacy concerns. []
Moderna announced that the FDA’s “refusal-to-file” letter from the FDA states the company’s application did not include an “adequate and well-controlled trial” because it did not compare the new vaccine to a licensed standard-dose flu vaccine, which the agency argued does not reflect “the best-available standard of care” in the US, particularly for older adults. []
Crucially, Moderna says the FDA did not identify safety or efficacy issues with the vaccine itself and that the study included additional data comparing the shot to a licensed high-dose vaccine for seniors. [] The company has requested an urgent meeting with the agency to clarify next steps.
"It's maliciously weaponizing 'evidence based medicine' with a sprinkle of idiot's epistemology," said a radiation-oncology resident @1337HxC via Reddit. Ahead: More reactions from today's practicing physicians.
Why this matters
Importantly, Moderna’s phase 3 data showed its mRNA flu vaccine was about 27% more effective than Fluarix in adults 50+, and in a separate trial demonstrated superior immune response and safety compared with a high-dose flu vaccine in adults 65+.[][]
This refusal is notable for several other reasons:
Rare regulatory step: A refusal-to-file is unusual for a biologics submission, especially one supported by extensive pre-submission discussions, signaling a stringent interpretation of clinical comparators. []
Comparator debate: The FDA’s insistence on the “best-available standard of care” comparator, while long a theoretical criterion, may now be more strictly enforced, affecting how vaccine trials are designed. []
Broader policy shifts: The decision comes amid broader changes in US vaccine policy under current Health and Human Services leadership, including increased scrutiny of mRNA technologies and alterations to routine immunization recommendations. []
Global context: Moderna’s mRNA influenza vaccine remains under active review in Europe, Canada, and Australia, suggesting divergent regulatory expectations globally. []
This action reflects evolving regulatory expectations that may influence future vaccine availability and the standards used to judge comparative effectiveness.
Related: The flu vaccine is now available for home use—here’s what physicians thinkReactions from those in the medical field
Healthcare practitioners took to Reddit to voice their concerns about the news in the r/medicine subreddit.
“It is hard not to see this as a push by RFK and his ilk's hatred for the mRNA technology. Seems to be worthwhile to at least review the vaccine rather [than] deny it. The administration is signaling it is against the Pfizer vaccine as well. Other countries are at least reviewing it,” said Reddit user @Lurkingdealfinder, an ICU nurse.
Emergency medicine physician @AllDayEmergency said, “Didn't have being on the same side as Big Pharma on my bingo card, but here I am.”
And Reddit user @ldnk, who works in a hospital’s ED, said, “Here's the thing. I'm open to harsher scrutiny toward pharmaceuticals. They aren't anyone's friends. They absolutely will push questionable efficacy if it means more money. But the heads of the FDA right now are charlatans. They are not rejecti[ng] based on sound literature. They are rejecting because they just don't want to.”
Your takeaway
What counts as “standard of care” may shape what reaches your patients: Regulators are signaling that in crowded vaccine spaces (eg, high-dose vs standard influenza vaccines for older adults), comparator choice must reflect the most current standard of care, not just an approved product. For clinicians involved in research or advising sponsors, this underscores the need to clarify what regulators will accept before enrollment begins, as those decisions can directly affect whether a product advances... or stalls.
Trial design affects access: Comparator selection is no longer just a scientific question, it’s a regulatory one. Misalignment with FDA expectations can lead to setbacks that delay potentially practice-changing tools.
Be ready to explain why promising vaccines aren’t yet available: Patients may hear about new mRNA options progressing abroad and ask why they’re not available in the US. This decision is a reminder that regulatory standards, not just efficacy signals, determine timelines. Clear communication about safety oversight and trial requirements can help manage expectations in the exam room.